samedan logo
 
 
 
spacer
home > ebr > summer 2019 > do more with less
PUBLICATIONS
European Biopharmaceutical Review

Do More With Less

The current advances in immunoncology are constantly rewriting the landscape of this field and changing the standard care of many types of cancer. Immunotherapy harnesses the immune system to fight cancer, and recent research has focused on teasing tumour cells out from their protective microenvironments by exposing them to the patient’s immune response, which has led to the development of new immunotherapies.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Katie Chapple is a Scientist at Sartorius Stedim Biotech, working within the technical development team. She joined the company in 2016, following the successful completion of a PhD in neuroimmunology at University of Glasgow, UK, which focused on the autoantibody response in multiple sclerosis. Katie’s current position builds on her already-rounded knowledge of assay development, with an emphasis on using complex immunoassays to better understand treatment responses. Her role focuses on flow cytometry assay development and using this platform as a powerful tool to characterise mAb’s MOA.

Andrea Gomez-Donart is an Associate Scientist in the cell analytics branch of Sartorius Stedim Biotech, working within the R&D assay development team. She joined Sartorius in 2018 after 18 years of research in the applied toxicology field, testing preclinical drugs for efficacy, toxicity, and biodistribution. Andrea is currently an active member of the assay development group, designing assay kits to be used on the IntelliCyt iQue® Screener Plus highthroughput flow cytometry platform.
spacer
Dr Katie Chapple
spacer
spacer
spacer
Andrea Gomez-Donart
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Thermo Fisher Scientific Completes Acquisition of PeproTech, a Leader in Recombinant Proteins

WALTHAM, Mass., Jan. 5, 2022 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, and PeproTech, Inc., a leading developer and manufacturer of recombinant proteins, today announced that Thermo Fisher completed its acquisition of PeproTech on December 30, 2021 for a total cash purchase price of approximately $1.85 billion.
More info >>

White Papers

Clinical Trial Labelling – More Than Just Labels

Faubel & Co. Nachfolger GmbH

Deciding which label is best for a particular trial project is not always easy. Labels have become multifunctional tools which are able to convey variable data in different languages, indicate first opening, product originality, support ease of use or blind study drugs. They are no longer used as mere carriers of specified contents.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement